PharmaTimes have reported that GlaxoSmithKline and Theravance have reported positive data from four Phase III trials assessing a combination therapy for maintenance treatment of COPD, making the once-daily pill closer to a regulatory filing.
The clinical trials involved more than 4,000 patients, including two 24-week efficacy trials comparing a combination of the long-acting muscarinic antagonist (LAMA) umeclidinium bromide and the long-acting beta-agonist (LABA) vilanterol. The date showed statistically significant improvements when compared with placebo and the individual parts in both trials, which tested difference doses.
Darrell Baker, SVP Respiratory Portfolio Optimisation Leader at GSK said “We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio…. These studies, together with our earlier dose-ranging work, give us confidence that this is a once-daily medicine with the potential to benefit many patients with COPD.
Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates